Clinical trials: Essential Hypertension.
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy.
- Trial name
- NCT05526703
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy.
- Trial name
- NCT01631227
- Testing
- Eprosartan, Eprosartan Mesylate
- Where
- 38 sites in Germany, Russia and 1 more
- Volunteers
- 665 people
- Sponsor
- Abbott
Hypertension
An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)
Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.
- Trial name
- NCT00449111
- Testing
- MK0954, losartan potassium / Duration of Treatment - 12 weeks
- Volunteers
- 11 people
- Sponsor
- Organon and Co
Primary Hypertension
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion.
- Trial name
- POTASSIUM (NCT01392534)
- Testing
- Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
- Where
- Poland
- Volunteers
- 1,586 people
- Sponsor
- Bayer
Essential Hypertension
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
- Trial name
- ALIAS (NCT01042392)
- Testing
- Aliskiren, Ramipril
- Where
- 98 sites in France
- Volunteers
- 506 people
- Sponsor
- Novartis
Essential Hypertension
Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension
As a third-generation dihydropyridine calcium channel blocker (CCB), Amlodipine is mainly used in a single therapy or combined therapy for hypertension or angina.
- Trial name
- NCT04554303
- Testing
- S-amlodipine 2.5mg, Amlodipine 5mg
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Essential Hypertension
A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
The purpose of this study is to evaluate the effect of atorvastatin on the pharmacokinetics of fimasartan.
- Trial name
- NCT00991705
- Testing
- Atorvastatin, Fimasartan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
High Dose BAYA1040_Nifedipine: a Dose-comparative Study
This is a clinical study evaluating the superiority in efficacy and assess safety and tolerability of BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) compared with BAYA1040_Nifedipine 40 mg/day (40 mg once daily) in patients…
- Trial name
- NCT01287260
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 22 sites in Japan
- Volunteers
- 352 people
- Sponsor
- Bayer
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy
The purpose of this study is to evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy in Essential Hypertension Patients
- Trial name
- NCT06121518
- Testing
- D064 and D702, QD
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT06465264
- Testing
- Allisartan Isoproxil/Amlodipine group 1, Amlodipine group 1, Allisartan Isoproxil/Amlodipine group 2
- Where
- China
- Volunteers
- 499 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension,Essential
First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension
The carotid body is located at the bifurcation of the internal and external carotid arteries. It is a chemoreceptor that plays a role in the sympathetic nervous system and in the development and maintenance of hypertension.
- Trial name
- NCT03314012
- Testing
- Catheter-Based Carotid Body Ablation
- Where
- 7 sites in Australia, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Cibiem, Inc.
Hypertension
Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension
The primary objective of this study is to investigate incremental cost effectiveness of Nifedipine CR and Amlodipine in combination therapy with Valsartan for the treatment of essential hypertensive patients.
- Trial name
- NCT01518855
- Testing
- Nifedipine (Adalat, BAYA1040), Amlodipine (Norvasc), Diovan
- Where
- 4 sites in Japan
- Volunteers
- 514 people
- Sponsor
- Bayer
Hypertension
To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension
The primary objective of this study is to compare the change from baseline in systolic blood pressure between KN060 and placebo in patients with essential hypertension over 12 weeks; the secondary objectives are to assess the…
- Trial name
- NCT07191899
- Testing
- KN060, 0.9% Sodium Chloride Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Alphamab Co., Ltd.
Essential Hypertension
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
- Trial name
- NCT00430950
- Testing
- olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg
- Where
- 41 sites in Belgium, Germany and 2 more
- Volunteers
- 1,011 people
- Sponsor
- Daiichi Sankyo
Hypertension
An Extension Trial of GW 906 in Participants With Essential Hypertension
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906
- Trial name
- NCT07879755
- Testing
- GW906
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Essential Hypertension, Healthy Volunteers
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of…
- Trial name
- NCT07803835
- Testing
- MWX401 1, MWX401 2, MWX401 3
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Primary Hypertension
Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension
The purpose of Iberis-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with primary hypertension by using Iberis multielectrode renal denervation system
- Trial name
- Iberis-HTN (NCT02901704)
- Testing
- Renal Denervation System (AngioCare)
- Volunteers
- 216 people
- Sponsor
- Shanghai AngioCare Medical
Essential Hypertension
Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
The fixed combination of verapamil SR/trandolapril (Tarka®) is an effective, well-tolerated therapy for the treatment of essential hypertension in those who require more than one agent to achieve optimal blood pressure (BP)…
- Trial name
- NCT01127139
- Where
- 134 sites in Czechia
- Volunteers
- 3,828 people
- Sponsor
- Abbott
Essential Hypertension
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values…
- Trial name
- NCT04470830
- Where
- South Korea
- Volunteers
- 718 people
- Sponsor
- Celltrion Pharm, Inc.
Essential Hypertension
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
This is a prospective, multicenter, blinded, randomized controlled clinical trial designed to evaluate the safety and efficacy of a single-use intravascular ultrasound ablation catheter and ultrasound ablation system in the…
- Trial name
- NCT07051811
- Testing
- Intravascular Ultrasound Ablation Therapy, Renal Artery Angiography
- Where
- 18 sites in China
- Volunteers
- 213 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.